Regulatory affairs Drug safety Production
Legal department
QP (PQR)
QC laboratory
After the implementation of corrective actions, the subsequent production batch should be reviewed by an ongoing study in addition to the normal yearly round of testing. The test parameters must be agreed on the basis of the individual situation. TEAMWORK As with PQR in general, ongoing stability testing requires the intensive exchange of information between the responsible persons and relevant specialist departments (see Figure 1). Responsibilities must be clearly laid down, and if external service providers are involved, appropriate technical agreements must be drawn up which define these responsibilities. The involvement of an external service provider may be beneficial to the marketing authorisation holder; expensive implementation of an in-house system can be avoided by employing the existing system of the service company. Investments and fixed costs are not increased, and the marketing authorisation holder can concentrate on its core competences such as marketing. Outsourcing all other functions is, in principle, possible (5). CONCLUSION The message to take away from this review is that expenditure, and hence production costs, can be minimised by sensible and skilled planning of the test protocol for ongoing stability testing. Note
Marketing authorisation holder
Figure 1: Interactions between specialist departments and external service providers
is likely to remain within the specified limits as testing continues. Here, statistical methods of regression an
d confidence interval analysis can be useful, although they should be used with caution. The results of ongoing stability testing have to be summarised in a report. All current results have to be compared with data from previous tests, for example from follow-up studies, and trend analyses have to be carried out (if applicable). The results have to be incorporated and discussed in the relevant PQR. It must also be noted that the manufacturing department (internal or contract manufacturer) and the Qualified Person responsible for market release have to be notified of the results of the ongoing stability studies. An appropriate SOP should specify what should be done in the case of out-of-specification (OOS) results and significant negative trends. If verified, they must be reported to the supervisory authorities. Further considerations should also be taken into account here, for example: N A review of sensitive or relevant areas in production should be undertaken to try to identify the cause and possible transmission to other batches/products A critical review of the labelled stability and, if necessary a recall of the affected product batch must be considered Measures to avoid errors should be discussed and implemented (corrective and protective actions, (CAPA)). In justified cases, other specialist personnel such as the Qualified Person for Pharmacovigilance will need to be involved
Thanks to Annemarie Jasper, PhD, and Christian Rieke for their helpful support. References 1. EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, doc.guandang.net eudralex/vol4_en.htm 2. Guideline on Stability Testing: Stability of Existing Active Substances and Related Finished Products (CPMP/QWP/122/02, rev 1) 3. Note for Guidance on Stability Testing of New Drug Substances and Products (CPMP/ICH/2736/99 corr) 4. Note for Guidance on Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Drug Products (CPMP/ICH/4104/00 adopted 2002/ ICH Q1D) 5. Sandner and Klöpf, Outsourcing in der Pharmaindustrie, Teil 1, Pharm Ind, 68, Nr 7, pp825-828, Teil 2, Pharm Ind, 68, Nr. 8, pp932-936, 2006
N
N
Sven Oliver Kruse, PhD, is Managing Director at Diapharm, responsible for the service laboratory Diapharm Analytics GmbH in Oldenburg (Germany). He entered the company in 2001 and accompanied the transition from a scientific institute to a service laboratory. He is also a Qualified Person for the company. Sven is a member of the Pharmaceutical-Technical Committee and the working parties‘Validation’ and‘PQR/Ongoing Stability’ at the German Medicines Manufacturers’ Association (BAH). He studied Pharmacy at the University of Münster (Germany) where he received his PhD in the field of phytochemistry research and analysis. He is also a member of the Society of Medicinal Plant Research, the Society of Phytotherapy and the German Pharmaceutical Society. Email: sven.kruse@diapha
rm.com
80
Innovations in Pharmaceutical Technology

DYNAMIC STABILITY TEST -- Calculate Formula - UL1083 油炸锅动态稳定性测试计算表_表格类模板_表格/模板_应用文书。DYNAMIC STABILITY TEST -- Calculate Formula...
EE Voltage Stability Test SOP(电压稳定性测试作业规范)_信息与通信_工程科技_专业资料。EE Voltage Stability Test SOP(电压稳定性测试作业规范)ISDDQAEE...
question to be discussed is whether the 2-D face stability test for interval matrices can be used to the stability test for the polytopes of matrices?...
Test Stability of Uster Advanced Fiber Information System(AFIS)_专业资料 暂无评价
? ? The test results generated by the stability studies will be evaluated ...Allow personnel who are more remotely involved in the daily maintenance of ...
www.Corrsys-Datron.com NHTSA Fishhook test www.Corrsys-Datron.com NHTSA Rollover Stability Steering wheel angle, roll stability triggered Steering wheel ...
test 酚含量试验 phenol content test 灰分含量试验 ash content test 储存稳定度试验 storage stability test 车辙试验 wheel rutting test 马歇尔稳定度试验 Marshall...
Test Product Shell Shock Experiments Hi-pot test Normal Temperature Test Module Defect Test Stability Test Drop Test Robustness of Terminations Test Aging ...
Kemgard MZM New Product Advisory SIGNIFICANT IMPROVEMENT IN SMOKE SUPPRESSION AND DYNAMIC STABILITY FOR RIGID PVC SYSTEMS KEMGARD MZM PROVIDES SUPERIOR SMOKE SUP...
The current drug stability test guideline Q1A (R2) issued by the International Conference on Harmonization (ICH) [7] suggests that stress studies should ...
热门文档